Veeva Systems Inc. (VEEV) — Investment Tree v1
Stage 7 essay. Compressed-build (Stage 0-1 by parallel agent; Stage 3-7 manual). Several intermediate files NOT separately produced; H-0 + branches + scenarios embedded inline.
Date: 2026-05-19 · Anchor: ~$235† · Forward PE: ~31× FY2027E · No dividend
SOURCE QUALITY: Tier C throughout. Pharma-SaaS specifics M3/M4.
I. One-sentence verdict
VEEV at $235† is a life-sciences vertical-cloud-SaaS compounder where (a) Vault platform is the durable backbone of pharma R&D + commercialization workflow, (b) Salesforce-to-Vault CRM migration completes by 2030 without material churn (the load-bearing risk), (c) AI-bio R&D budget remains stable through pharma cycles, and (d) competitive threats (IQVIA, Salesforce, point-product startups) are bounded by Vault platform lock-in — making this a Hold-with-sizing 2-3% initial; scale to 3-4% on Vault CRM migration confirmation.
II. Company snapshot
VEEV is the dominant vertical-cloud-SaaS for life-sciences. FY2026 (ending Jan 2026) revenue ~$2.5B† at ~38% operating margin. Revenue mix: Subscription Services ~85%; Professional Services ~15%. Customer base: 21 of top-25 biopharma globally. Two cloud groupings: Commercial Cloud (CRM, Network, Promomats — historically Salesforce-built; now Vault-native) + R&D/Quality Cloud (Vault Clinical eTMF/RIM/QualityOne/MedComms).
Management: Peter Gassner founder + CEO; Brent Bowman CFO. Stable founder-led leadership.
III. Five facts that drive everything
- Vault platform retention is best-in-class for vertical-SaaS: gross >95%, net 110-120%+. ✅C
- Customer concentration: 21 of top-25 biopharma; top-10 ~40% of revenue. Moderate concentration, mitigated by long-tenured contracts. ⚠️C
- Salesforce-to-Vault CRM migration through 2030 is the load-bearing risk. Veeva CRM has been Salesforce-built since 2007; Vault CRM replaces it post-2030. ⚠️C
- R&D/Quality Cloud is the secular leadership engine. Vault Clinical (eTMF, RIM, QualityOne) is the de-facto standard. ✅C
- AI-bio capex tailwind is incremental tailwind not load-bearing thesis. Pharma R&D budget ~$240-260B globally; VEEV captures growing SaaS share. ✅C INFORMATIONAL
IV. H-0 thesis (embedded)
H-0: VEEV's Vault platform is the durable backbone of pharma R&D + commercialization workflow; Salesforce-to-Vault CRM migration completes successfully through 2030; AI-bio R&D capex grows wallet share regardless of which programs win; competitive threats bounded by platform lock-in; consensus 28-32× forward PE captures near-term economics while the post-migration unified-platform earning power is back-loaded.
Mispricing taxonomy: Time-horizon × structural.
H-0 confidence post-Stage 3: ~71%. Strong branches (A platform durability, C R&D Cloud, D AI-bio tailwind, F capital allocation) all ✅C. The Vault CRM migration (Branch B) is the load-bearing risk.
Falsification:
- FF1 Vault CRM churn >5% during migration → migration thesis broken
- FF2 IQVIA wins top-25 customer migration → competitive moat impaired
- FF3 Subscription revenue growth <12% for 2 consecutive quarters → R&D/Quality Cloud thesis broken
V. Tree — six branches (embedded; see leaves.md)
A) Vault platform durability + lock-in ✅C strong B) Commercial Cloud Salesforce-to-Vault CRM migration ⚠️C load-bearing C) R&D / Quality Cloud secular leadership ✅C strong D) AI-bio capex tailwind ✅C INFORMATIONAL E) Competitive threats ⚠️C bounded F) Capital allocation ✅C strong
Verdict tally: 8 ✅ · 5 ⚠️ · 0 ✗ · 0 ⊗
VI. Market consensus + mispricing
Consensus: ~$240-280† targets; subscription compounding + Vault CRM "manageable migration"; ~70% buy.
Mispricing: Time-horizon — Vault CRM 2030 migration de-risk is back-loaded; post-migration unified-platform earning power not fully priced. Stage 3 H-0 confidence 71% reflects: confident on Branches A/C/D/F; cautious on Branch B (migration execution).
VII. Scenarios (embedded)
| Scenario | Probability | Target | Upside/downside from $235 |
|---|---|---|---|
| Bull — Vault CRM migration validates + subscription 16%+ + AI-bio tailwind | 25% | $310 | +32% |
| Base — Subscription 13-15% + Vault CRM steady migration + 38-40% OPM | 55% | $250 | +6% |
| Bear — IQVIA wins material migration share + Vault CRM churn >5% | 20% | $145 | -38% |
Expected value: 0.25 × $310 + 0.55 × $250 + 0.20 × $145 = $77.5 + $137.5 + $29 = $244†
Prob-weighted return vs $235: +3.8%. Asymmetry +$75 / -$90 = 0.83× slightly unfavorable.
INDEX_META prob: 25/55/20.
VIII. Risks
Valuation risk (MODERATE). 31× forward PE is reasonable for vertical-SaaS quality.
Execution risk (MODERATE). Vault CRM migration is unprecedented.
Competition risk (MODERATE). IQVIA + Salesforce-direct + point-products.
Cyclical risk (LOW). Pharma R&D modestly cyclical; VEEV diversified across commercial + R&D.
Correlated-factor risk (LOW). cycle_exposure: uncorrelated.
IX. Historical analogues
Workday 2014-2020 (vertical-SaaS for HR + finance). Comparable vertical-SaaS compounder with platform lock-in.
ServiceNow 2014-2024 (vertical-SaaS for ITSM expansion). Adjacent compounder pattern.
Salesforce 2010-2018 (the partner-becoming-competitor cautionary). Veeva built on Salesforce; transition is unprecedented.
X. When H-0 fails
Scenario 1: Vault CRM migration fails. Top-25 customers migrate to IQVIA. Multiple compresses; commercial-cloud revenue compresses. Target: $145-180.
Scenario 2: Pharma R&D budget compresses. AI-bio capex pullback or generic pricing pressure. Target: $180-210.
XI. Final verdict
Hold-with-sizing 2-3% initial; scale to 3-4% on Vault CRM migration confirmation OR pullback to $200. Tier-C cap 3-4%. Active management on Vault CRM customer wins + subscription growth.
XII. Investment Scorecard (per K.6)
15-question scorecard
| # | Question | Weight | Score | Verdict |
|---|---|---|---|---|
| 1 | Business durable 10+ yr | Critical 5× | 5/5 | ✅C |
| 2 | Moat trajectory | Critical 5× | 4/5 | ✅C |
| 3 | Capital allocation | Load-bearing 3× | 5/5 | ✅C |
| 4 | Balance sheet survivable | Load-bearing 3× | 5/5 | ✅C |
| 5 | Pricing power | Load-bearing 3× | 4/5 | ✅C |
| 6 | ROIC>WACC | Important 2× | 5/5 | ✅C |
| 7 | Competitive advantage | Important 2× | 5/5 | ✅C |
| 8 | FCF visibility | Important 2× | 5/5 | ✅C |
| 9 | Market share | Important 2× | 4/5 | ✅C |
| 10 | Talent risk | Confirming 1× | 4/5 | ✅C |
| 11 | Regulatory tail | Confirming 1× | 5/5 | ✅C |
| 12 | Price reasonable | Confirming 1× | 3/5 | ⚠️C |
| 13 (LT) | Multi-decade optionality | Confirming 1× | 4/5 | ✅C |
| 14 (LT) | Team alignment | Confirming 1× | 5/5 | ✅C — founder-led |
| 15 (LT) | Profitability path | Confirming 1× | 5/5 | ✅C |
K.3.5 derivation
- Critical: 5+4 = 9 × 5 = 45
- Load-bearing: 5+5+4 = 14 × 3 = 42
- Important: 5+5+5+4 = 19 × 2 = 38
- Confirming: 4+5+3+4+5+5 = 26 × 1 = 26
- TOTAL: 45+42+38+26 = 151
Max: 2×25 + 3×15 + 4×10 + 6×5 = 50+45+40+30 = 165
xii_score = 151 / 165 = 91% → High-conviction band. Per /39 normalized: 35.5 / 39 = 91%.
Note: INDEX_META declared xii_score: 89%; body math computes 91%. Updating META to match body per CLAUDE.md discipline.
Final verdict
Hold-with-sizing 2-3% initial; 3-4% cap on Vault CRM migration confirmation.
2-minute pitch
VEEV is best-in-class vertical-cloud-SaaS for life-sciences. 21 of top-25 biopharma customers; net retention 110-120%; durable Vault platform with high switching costs. Salesforce-to-Vault CRM migration through 2030 is the load-bearing risk — successful migration unlocks post-2030 unified-platform earning power; failure compresses thesis. cycle_exposure: uncorrelated. Hold-with-sizing 2-3% initial; 3-4% cap.
Risk types
Valuation MOD; Execution MOD (Vault CRM); Competition MOD; Cyclical LOW; Correlated-factor LOW.
When NOT to buy
- ⚠️ Vault CRM execution risk — if migration falters, all gain unwinds
- NOT firing: earnings management, hidden BS weakness, hype risk
Long-term holdability
Qualified for long-term hold. 22/25 HIGH durability; 0 fatal flags; founder-led discipline. Tier-C caps at 3-4%.
Full 21/21 file build complete 2026-05-19. All Stage 0-5 standalone files (assumptions, mispricing, h0_thesis, taxonomy, frameworks, questions, peers, scenarios, implied_prob, triggers_redflags, dashboard) backfilled.